A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naive and PR Prior Treatment Failure Subjects With Chronic HCV GT1, 4 or 6 Infection
Latest Information Update: 13 May 2022
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Peginterferon alfa-2b; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms C-EDGE Head-to-Head
- Sponsors Merck Sharp & Dohme
- 11 Apr 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
- 19 Feb 2019 Results of integrated analysis of data from 12 international phase 2/3 clinical trials(NCT01717326,NCT01932762,NCT02092350,NCT02105467,NCT02105662,NCT02105688,NCT02105701,NCT02115321,NCT02203149,NCT02251990,NCT02252016 and NCT02358044) assessing safety and efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection published in the Journal of Gastroenterology and Hepatology
- 16 Aug 2016 Results published in the Journal of Hepatology.